Biotechs jockey for gene therapy lead with hemophilia data ‘snapshots’

red blood cells
Breaking

Generally it takes a readout from a completed trial to gain any important insights into the potential of an experimental drug. Unless you’re in a field like gene therapy, where the responses of even tiny numbers of patients are used to grab the spotlight in a market that’s seemingly insatiable for news. Add in a horse race environment on the data front, with competitors looking to establish a clear lead in a hot field, and the rivalry heats up on a patient-by-patient basis.

Enter Spark Therapeutics, which is making a bid to become the first gene therapy company to pitch a product to the FDA.

On Thursday, Spark--which is partnered with Pfizer ($PFE)--trotted out data on three hemophilia B patients enrolled in a Phase I/II study. Hemophilia patients are at risk of uncontrolled bleeding because they lack a clotting agent known as Factor IX. And following gene therapy with SPK-9001, they demonstrated Factor IX levels of 28%, 30% and 16% of normal. Those were the numbers that went into an abstract ahead of a June 11 presentation at a meeting of the European Hematology Association, and the biotech achieved considerable attention for the results with a release and media outreach.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

As a result, its stock ($ONCE) surged 15% by the end of the day.

One of the reasons why it scored is because the numbers beat out a competitor. UniQure ($QURE) played this game back in January, when it noted that two hemophilia B patients had Factor IX expression levels of 5.5% and 4.5%. Like Spark, uniQure claimed a success, highlighting historical data that suggest 5% is the mark you need to hit to demonstrate a meaningful impact for patients. At Spark, the historical number to beat is 12%.

All the data are intriguing, and none of them are conclusive. Historical comparisons in lieu of a control arm can be controversial and frequently conflicting. Gene therapy in particular will be priced high on the notion that one treatment could provide long-term results, if not a cure. But there’s little insight on durability from preliminary data. And there’s no telling if the final readout will be anywhere near as promising as the snapshot.

This is also a crowded field, with each player looking to distinguish itself. Biogen ($BIIB) focused on hemophilia A and B early, bringing in pioneer researcher Olivier Danos to run its fast-growing gene therapy group. Baxalta released early data on BAX 335 last year, while Dimension Therapeutics may be the next company with early data to report. And BioMarin ($BMRN) has been making early tracks with its hemophilia A gene therapy effort.

For BioMarin, which has claimed a leading role in hemophilia A with the first program in the clinic, the snapshot proffered a few weeks ago includes 6 patients who had achieved Factor VIII expression over 5% (their bar for success), with two over 50%.

This is one race that’s just going into its first turn, but the jockeying is already intense.

 

Related Articles:
Gene therapy player Spark eyes a groundbreaking approval by 2017
Pfizer buys into gene therapy's renaissance and bets on Spark Therapeutics
Spark nails a $161M IPO to fund its 'breakthrough' gene therapy

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.